StockNews.com Begins Coverage on OpGen (NASDAQ:OPGN)

Stock analysts at StockNews.com assumed coverage on shares of OpGen (NASDAQ:OPGN) in a research report issued to clients and investors on Saturday. The brokerage set a “sell” rating on the medical research company’s stock.

OpGen Price Performance

OPGN opened at $2.24 on Friday. The firm has a 50 day simple moving average of $2.45 and a 200 day simple moving average of $3.81. OpGen has a fifty-two week low of $1.75 and a fifty-two week high of $38.40.

OpGen (NASDAQ:OPGN) last issued its earnings results on Monday, August 19th. The medical research company reported ($1.18) EPS for the quarter. OpGen had a negative net margin of 1,140.36% and a negative return on equity of 1,827.76%. The firm had revenue of $0.03 million during the quarter.

Institutional Investors Weigh In On OpGen

An institutional investor recently bought a new position in OpGen stock. Chase Investment Counsel Corp bought a new position in shares of OpGen, Inc. (NASDAQ:OPGN) in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 331,890 shares of the medical research company’s stock, valued at approximately $230,000. Chase Investment Counsel Corp owned about 2.63% of OpGen at the end of the most recent quarter. Hedge funds and other institutional investors own 2.68% of the company’s stock.

OpGen Company Profile

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.